Last edition
News about
Sanofi Receives Nod for IMOVAX-Polio in India
Sanofi has gained approval for IMOVAX-Polio, an alternative injectable vaccine.
Aptar Pharma Gets NMPA Nod for Airless Drug Delivery System
Aptar Pharma has received approval by the National Medical Products Administration (NMPA) in China of Sinomune Pharmaceutical’s Li Fu metronidazole gel.
Strides Pharma Receives FDA Approval for Antidepressant Drug
Strides Pharma Science’s subsidiary has gained approval from the US health regulator to market a generic antidepressant medication.
Sartorius and TheWell Bioscience to Enable More Accurate Predictions in Drug Discovery
Sartorius has teamed up with TheWell Bioscience on the further development of hydrogels and bioinks tailored to produce 3D advanced cell models for drug discovery workflows.
Lupin Rolls Out First Generic Version of Oracea
Lupin has unveiled the first generic version of Oracea (Doxycycline Capsules, 40 mg), in the United States.
MOLLI Surgical Introduces OncoPen: A Revolutionary Tool in Breast Cancer Surgery
This sleek, pen-like wand seamlessly integrates with the acclaimed MOLLI® 2 System, providing sophisticated tools for precisely targeting and removing cancerous lesions.
This heart arrhythmia, affecting millions worldwide, has seen a revolutionary approach after receiving approval from the US Food and Drug Administration.
Nvelop Therapeutics to Launch Dual Platforms for In Vivo Delivery of Next-Gen of Genetic Medicines
Nvelop Therapeutics has officially announced to develop the next generation of genetic medicines for a wide range of diseases.
Invenra Signs Research Deal with Astellas Pharma to Boost Bispecific Therapeutic Research
Invenra Inc. has forged a strategic research agreement with Astellas Pharma, a global pharmaceutical company with a vision to turn innovative science into value for patients.
AustinPx Invests in Pharmaceutics and Manufacturing Capabilities to Boost Drug Development
The latest investments enhance AustinPx’s early phase development and manufacturing capabilities by enabling faster timelines, improved stability, and reduced risk.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy